Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
The FDA recently approved idecabtagene vicleucel for the treatment of which type of cancer?
The FDA has approved isatuximab-irfc plus carfilzomib and dexamethasone for the treatment of adults with relapsed/refractory MM given 1 to 3 previous lines of therapy.
The FDA approved idecabtagene vicleucel for the treatment of patients with multiple myeloma who have not responded to, or whose disease has returned after, at least 4 prior lines of therapy.
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, S. Vincent Rajkumar, MD, discussed the frontline therapy of MM for transplant-ineligible patients.
True or False: Ixazomib, an oral proteasome inhibitor, is ideal for multiple myeloma treatment due to a history of low rates of polyneuropathy and patient tolerability.
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
Available clinical data presented at the virtual 2020 ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/…